Radiopharm extends radioimmunotherapy trial to 5 more cancer types
Radiopharm Theranostics Ltd has received approval to extend its Phase 1 trial of Lu-RAD204 to five more cancer types
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results